Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Cell Discovery

Volumn 6, Issue 1, 2020, Pages

  Zhou, Yadi ^a   Hou, Yuan ^a   Shen, Jiayu ^a   Huang, Yin ^a   Martin, William ^a   Cheng, Feixiong ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DACTINOMYCIN; EMODIN; IMMUNOSUPPRESSIVE AGENT; MELATONIN; MERCAPTOPURINE; NUCLEOCAPSID PROTEIN; RAPAMYCIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CORONAVIRIDAE; CORONAVIRINAE; DRUG REPOSITIONING; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS MORPHOLOGY;

EID: 85082021457     PISSN: 20565968     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/s41421-020-0153-3     Document Type: Article

References (97)

1. Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S. & Yuen, K. Y. Coronaviruses—drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327–347 (2016).
2. Paules, C. I., Marston, H. D. & Fauci, A. S. Coronavirus infections—more than just the common cold. JAMA 323, 707–708 (2020).
3. de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
4. de Wilde, A. H., Snijder, E. J., Kikkert, M. & van Hemert, M. J. Host factors in coronavirus replication. Curr. Top. Microbiol. Immunol. 419, 1–42 (2018).
5. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
6. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 10.1056/NEJMoa2001316 (2020) (in press).
7. Greene, J. A. & Loscalzo, J. Putting the patient back together—social medicine, network medicine, and the limits of reductionism. N. Engl. J. Med. 377, 2493–2499 (2017).
8. Avorn, J. The $2.6 billion pill-methodologic and policy considerations. N. Engl. J. Med. 372, 1877–1879 (2015).
9. Cheng, F. In silico oncology drug repositioning and polypharmacology. Methods Mol. Biol. 1878, 243–261 (2019).
10. Cheng, F., Hong, H., Yang, S. & Wei, Y. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Brief Bioinformatics 18, 682–697 (2017).
11. Cheng, F., Murray, J. L. & Rubin, D. H. Drug repurposing: new treatments for Zika virus infection? Trends Mol. Med. 22, 919–921 (2016).
12. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
13. Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).
14. Cheng, F. et al. Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis. PLoS Comput. Biol. 12, e1005074 (2016).
15. Yang, S., Fu, C., Lian, X., Dong, X. & Zhang, Z. Understanding human-virus protein-protein interactions using a human protein complex-based analysis framework. mSystems 4, e00303 (2019).
16. Liu, C. et al. Computational network biology: data, models, and applications. Phys. Rep. 10.1016/j.physrep.2019.12.004 (2020) (in press).
17. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4893 (2014).
18. Johansen, L. M. et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5, 190ra179 (2013).
19. He, S. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med. 7, 282ra249 (2015).
20. Barrows, N. J. et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host. Microbe 20, 259–270 (2016).
21. Xu, M. et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. 22, 1101–1107 (2016).
22. Cheng, F. et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8, e1002503 (2012).
23. Cheng, F. et al. A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat. Commun. 10, 3476 (2019).
24. Zeng, X. et al. deepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics 35, 5191–5198 (2019).
25. Zeng, X. et al. Target identification among known drugs by deep learning from heterogeneous networks. Chem. Sci. 11, 1775–1797 (2020).
26. Zeng, X. et al. Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest. Bioinformatics 10.1093/bioinformatics/btaa010 (2020) (in press).
27. Fang, J. et al. Network-based translation of GWAS findings to pathobiology and drug repurposing for Alzheimer’s disease. MedRxiv. 10.1101/2020.01.15.20017160 (2020).
28. Cheng, F., Kovacs, I. A. & Barabasi, A. L. Network-based prediction of drug combinations. Nat. Commun. 10, 1197 (2019).
29. Forni, D., Cagliani, R., Clerici, M. & Sironi, M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 25, 35–48 (2017).
30. Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 (2019).
31. Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864–1868 (2005).
32. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
33. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 10.1038/s41586-020-2012-7 (2020).
34. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 10.1126/science.abb2507 (2020).
35. Chang, C. K., Chen, C. M., Chiang, M. H., Hsu, Y. L. & Huang, T. H. Transient oligomerization of the SARS-CoV N protein-implication for virus ribonucleoprotein packaging. PLoS ONE 8, e65045 (2013).
36. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
37. Lasso, G. et al. A structure-informed atlas of human-virus interactions. Cell 178, 1526–1541.e1516 (2019).
38. de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875–4884 (2014).
39. Zhao, Y. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169–172 (2016).
40. Emmott, E. et al. The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology. J. Virol. 87, 9486–9500 (2013).
41. V’Kovski, P. et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. Elife 8, e42037 (2019).
42. Moskowitz, D. W. & Johnson, F. E. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr. Top. Med. Chem. 4, 1433–1454 (2004).
43. Seko, Y. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. Clin. Sci. 110, 379–386 (2006).
44. Erlandson, K. M. et al. The impact of statin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy on cognitive function in adults with human immunodeficiency virus infection. Clin. Infect. Dis. 65, 2042–2049 (2017).
45. Wang, X. J. et al. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. Antivir. Res. 120, 140–146 (2015).
46. Ko, C. et al. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir. Ther. 20, 835–842 (2015).
47. Hong, M. et al. Identification of a novel transcriptional repressor (HEPIS) that interacts with nsp-10 of SARS coronavirus. Viral Immunol. 21, 153–162 (2008).
48. McNulty, S., Flint, M., Nichol, S. T. & Spiropoulou, C. F. Host mTORC1 signaling regulates andes virus replication. J. Virol. 87, 912–922 (2013).
49. Stohr, S. et al. Host cell mTORC1 is required for HCV RNA replication. Gut 65, 2017–2028 (2016).
50. Wang, C. H. et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit. Care Med. 42, 313–321 (2014).
51. Dyall, J. et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs 77, 1935–1966 (2017).
52. Karran, P. & Attard, N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer 8, 24–36 (2008).
53. Chen, X., Chou, C. Y. & Chang, G. G. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir. Chem. Chemother. 19, 151–156 (2009).
54. Cheng, K. W. et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antivir. Res. 115, 9–16 (2015).
55. Chen, H., Wurm, T., Britton, P., Brooks, G. & Hiscox, J. A. Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell. J. Virol. 76, 5233–5250 (2002).
56. Rainsford, K. D. Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology 14, 2–9 (2006).
57. Garcia, C. C., Guabiraba, R., Soriani, F. M. & Teixeira, M. M. The development of anti-inflammatory drugs for infectious diseases. Discov. Med. 10, 479–488 (2010).
58. Silvestri, M. & Rossi, G. A. Melatonin: its possible role in the management of viral infections-a brief review. Ital. J. Pediatr. 39, 61 (2013).
59. Srinivasan, V., Mohamed, M. & Kato, H. Melatonin in bacterial and viral infections with focus on sepsis: a review. Recent Pat. Endocr. Metab. Immune Drug Discov. 6, 30–39 (2012).
60. Tan, D. X., Korkmaz, A., Reiter, R. J. & Manchester, L. C. Ebola virus disease: potential use of melatonin as a treatment. J. Pineal Res. 57, 381–384 (2014).
61. Tan, D. X., Manchester, L. C., Terron, M. P., Flores, L. J. & Reiter, R. J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res. 42, 28–42 (2007).
62. Galano, A., Tan, D. X. & Reiter, R. J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J. Pineal Res. 54, 245–257 (2013).
63. Xiao, J., Shimada, M., Liu, W., Hu, D. & Matsumori, A. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur. J. Heart Fail. 11, 349–353 (2009).
64. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 10.1038/s41422-020-0282-0 (2020).
65. Tan, X. et al. Systematic identification of synergistic drug pairs targeting HIV. Nat. Biotechnol. 30, 1125–1130 (2012).
66. Kindrachuk, J. et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob. Agents Chemother. 59, 1088–1099 (2015).
67. Lewis, E. L., Harbour, D. A., Beringer, J. E. & Grinsted, J. Differential in vitro inhibition of feline enteric coronavirus and feline infectious peritonitis virus by actinomycin D. J. Gen. Virol. 73, 3285–3288 (1992).
68. Zhou, W. B., Ding, Q., Chen, L., Liu, X. A. & Wang, S. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res. Treat. 128, 625–631 (2011).
69. Cong, Y. et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS ONE 13, e0194868 (2018).
70. Schwarz, S., Wang, K., Yu, W., Sun, B. & Schwarz, W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antivir. Res. 90, 64–69 (2011).
71. Ho, T. Y., Wu, S. L., Chen, J. C., Li, C. C. & Hsiang, C. Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir. Res. 74, 92–101 (2007).
72. Lambert, D. W., Clarke, N. E., Hooper, N. M. & Turner, A. J. Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett. 582, 385–390 (2008).
73. Dai, J., Inscho, E. W., Yuan, L. & Hill, S. M. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J. Pineal Res. 32, 112–119 (2002).
74. Fung, T. S. & Liu, D. X. Activation of the c-Jun NH2-terminal kinase pathway by coronavirus infectious bronchitis virus promotes apoptosis independently of c-Jun. Cell Death Dis. 8, 3215 (2017).
75. Biedenkopf, N. et al. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antivir. Res. 137, 76–81 (2017).
76. Muller, C. et al. Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antivir. Res. 150, 123–129 (2018).
77. Halder, A. K., Dutta, P., Kundu, M., Basu, S. & Nasipuri, M. Review of computational methods for virus-host protein interaction prediction: a case study on novel Ebola-human interactions. Brief. Funct. Genomics 17, 381–391 (2018).
78. Bedi, O., Dhawan, V., Sharma, P. L. & Kumar, P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch. Pharmacol. 389, 695–712 (2016).
79. Li, Q. et al. Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog. 10, e1004163 (2014).
80. Gebre, M., Nomburg, J. L. & Gewurz, B. E. CRISPR-Cas9 genetic analysis of virus-host interactions. Viruses 10, 55 (2018).
81. Kim, J. H. et al. Acute eosinophilic pneumonia related to a mesalazine suppository. Asia Pac. Allergy 3, 136–139 (2013).
82. Gupta, A. & Gulati, S. Mesalamine induced eosinophilic pneumonia. Respir. Med. Case Rep. 21, 116–117 (2017).
83. Chiang, C. W. et al. Translational high-dimensional drug interaction discovery and validation using health record databases and pharmacokinetics models. Clin. Pharmacol. Ther. 103, 287–295 (2018).
84. Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 35, 1547–1549 (2018).
85. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
86. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).
87. Yang, H. et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 44, D1069–D1074 (2016).
88. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).
89. Liu, T. Q., Lin, Y. M., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35, D198–D201 (2007).
90. Pawson, A. J. et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 42, D1098–D1106 (2014).
91. Apweiler, R. et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 32, D115–D119 (2004).
92. Coordinators, N. R. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 44, D7–D19 (2016).
93. Smith, I. N., Thacker, S., Seyfi, M., Cheng, F. & Eng, C. Conformational dynamics and allosteric regulation landscapes of germline PTEN mutations associated with autism compared to those associated with cancer. Am. J. Hum. Genet. 104, 861–878 (2019).
94. Reghunathan, R. et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol. 6, 2 (2005).
95. Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4, e00165–00113 (2013).
96. Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10, 120 (2019).
97. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).